Terazaki Yasuhiro, Nagamatsu Hironori, Ono Hironori, Iwakuma Nobutaka, Shirouzu Kazuo
Dept. of Surgery, Ohmuta National Hospital.
Gan To Kagaku Ryoho. 2005 May;32(5):675-7.
We report a case of good response to chemo-endocrine therapy with slight alopecia. A 55-year-old woman was diagnosed as advanced breast cancer with T4c, N3, M1, Stage IV, who was left cervical node-positive. She received 4 cycles of CTF (cyclophosphamide 100 mg/body/day 1-14, THP 30 mg/body/days 1,8, and 5-FU 750 mg/body/days 1, 8 4 wq) therapy in addition to oral tamoxifen (20 mg/body) administration. After this treatment, the primary tumor was markedly reduced (PR), and only slight alopecia was observed. Generally, 3 cycles of CAF (CEF) therapy induced severe alopecia (grade 3). But this CTF regimen caused grade 1 alopecia. Most women have strong resistance to alopecia. It seems that the quality of life for breast cancer patients was affected by the extent of the alopecia. Therefore, CTF therapy should be considered effective for advanced breast cancer patients while reducing the extent of alopecia.
我们报告了一例对化疗联合内分泌治疗反应良好且仅有轻微脱发的病例。一名55岁女性被诊断为晚期乳腺癌，T4c、N3、M1，IV期，左颈部淋巴结阳性。除口服他莫昔芬（20mg/体）外，她接受了4个周期的CTF（环磷酰胺100mg/体/第1 - 14天，吡柔比星30mg/体/第1、8天，氟尿嘧啶750mg/体/第1、8天，每4周重复）治疗。经过该治疗后，原发肿瘤明显缩小（PR），仅观察到轻微脱发。一般来说，3个周期的CAF（CEF）治疗会导致严重脱发（3级）。但这种CTF方案导致1级脱发。大多数女性对脱发有较强的抵抗力。乳腺癌患者的生活质量似乎受到脱发程度的影响。因此，CTF治疗对于晚期乳腺癌患者在减少脱发程度的同时应被视为有效。
